Our Approach

our approach

Our advisory work starts from a position of respect
for our clients' organization, people,
products and science.


our approach

We have devoted our careers to the life
sciences industry and have the deepest respect
and admiration for the participants in it.


our approach

We are a very active advisor in the market.
Torreya Partners has successfully closed over
100 assignments since our founding in 2007.

Our Perspective

our approach

We often take an operating perspective
to strategic and transaction work.


Royalty Monetization

$22 million

December 2016

North America

Opiant Pharmaceuticals

Partial Royalty Monetization

$17.5 million

December 2016

North America

Rubicon Research

Equity Sale

$33 million

November 2016

North America

September 13-15, 2017

BAML Global Healthcare Conference

London, UK

September 25, 2017

Sachs MedTech & Digital Health Forum

Basel, Switzerland

September 26-27, 2017

BioPharm America

Boston, MA

July 27, 2017

Update on Torreya’s recent activity advising on M&A, capital markets and licensing transactions.


December 21, 2016

XOMA Announces up to $22 Million Generated from Sale of Royalty Streams from Two License Agreements to HealthCare Royalty Partners and Provides Corporate Update


December 15, 2016

Opiant Pharmaceuticals, Inc. Announces NARCAN® Nasal Spray Royalty Monetization